Brief: Fresh Tracks Therapeutics Announces Positive Topline Results From Single And Multiple Ascending Dose Parts Of Phase 1 Study Of Oral Dyrk1a Inhibitor Frtx-02
07/03/2023 21:19
March 7 (Reuters) - Fresh Tracks Therapeutics Inc FRTX.O :
* FRESH TRACKS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE
RESULTS
FROM SINGLE AND MULTIPLE ASCENDING DOSE PARTS OF PHASE 1 STUDY
OF ORAL DYRK1A INHIBITOR FRTX-02
* FRESH TRACKS THERAPEUTICS: FRTX-02 WAS GENERALLY SAFE AND
WELL
TOLERATED WITHIN POTENTIAL THERAPEUTIC DOSE RANGE, MEETING
STUDY'S PRIMARY OBJECTIVES
* FRESH TRACKS THERAPEUTICS INC: EVALUATING STRATEGIC
OPTIONS TO
FURTHER DEVELOP FRTX-02 AND MAXIMIZE SHAREHOLDER VALUE
* FRESH TRACKS THERAPEUTICS: REDUCTION IN DISEASE-RELEVANT
CYTOKINES OBSERVED IN EXPLORATORY EX-VIVO LPS-STIMULATED WHOLE
BLOOD PHARMACODYNAMIC ASSAYS
Source text for Eikon: ID:nGNX7hdhlQ
Further company coverage: FRTX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Fresh Tracks Therapeutics
See all newsBrief: Fresh Tracks Therapeutics Announces Second Adjournment Of Special Meeting Of Stockholders
Brief: Fresh Tracks Therapeutics Intends To Seek Judicial Dissolution If Liquidation And Approved By Stockholders
Brief: Fresh Tracks Therapeutics Q3 EPS USD 0.32
Brief: Fresh Tracks Therapeutics Inc On October 10 Received A Notice From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Gold miners, Goosehead Insurance, FedEx